Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 6/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 4/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 3/20 | 0.32 |
| ▸ | MMP8 | P22894 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381992 | 0.89 | SLC15A2 (0.44) | SLC15A2RENMMP2MMP9 | |
| SCHEMBL27624894 | 0.88 | REN (0.44) | SLC15A2RENPTPN1MMP1 | |
| SCHEMBL29720798 | 0.87 | SLC15A2 (0.42) | SLC15A2RENMMP2MMP9 | |
| SCHEMBL2811070 | 0.86 | SLC15A2 (0.36) | SLC15A2 | |
| Bromide SCHEMBL11338174 | 0.86 | BIRC2 (0.42) | — | |
| SCHEMBL30943804 | 0.85 | CTSD (0.40) | SLC15A2REN | |
| SCHEMBL2815083 | 0.84 | SLC15A2 (0.54) | SLC15A2MMP1 | |
| SCHEMBL2243005 | 0.84 | SLC15A2 (0.54) | SLC15A2MMP1 | |
| SCHEMBL4588256 | 0.84 | SLC15A2 (0.36) | SLC15A2 | |
| SCHEMBL16297738 | 0.84 | MMP2 (0.38) | RENMMP2MMP1MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070110693-A1 | COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND SOFT TISSUE FILLERS, AND METHODS RELATED THERETO | PROCYTE CORPORATION (US) | 2007-05-17 | — | — | US | disclosed |
| US-20040063616-A1 | Compositions containing peptide copper complexes and soft tissue fillers, and methods related thereto | PROCYTE CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063616-A1 | Compositions containing peptide copper complexes and soft tissue fillers, and methods related thereto | CUTA, PLOD3, FN1 | SLC15A2 1409/4885REN 4092/4885PTPN1 2617/4885 |
| US-20070110693-A1 | COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND SOFT TISSUE FILLERS, AND METHODS RELATED THERETO | CUTA, PLOD3, FN1 | SLC15A2 1409/4885REN 4092/4885PTPN1 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.